false
0001847345
0001847345
2025-06-17
2025-06-17
0001847345
dei:FormerAddressMember
2025-06-17
2025-06-17
0001847345
ASBP:CommonStockParValue0.0001PerShareMember
2025-06-17
2025-06-17
0001847345
ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember
2025-06-17
2025-06-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 17, 2025
Aspire Biopharma
Holdings, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware |
|
001-41293 |
|
33-3467744 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission
File No.) |
|
(I.R.S. Employer
Identification No.) |
23150 Fashion Drive, Suite 232
Estero, Florida 33928
(Address of Principal Executive Offices)
(415) 592-7399
(Registrant’s Telephone Number)
194 Candelaro Drive, #233
Humacao, Puerto Rico 00791
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common stock, par value $0.0001 per share |
|
ASBP |
|
The Nasdaq Stock Market LLC |
| Warrants, each exercisable for one share of common stock |
|
ASBPW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01 Other Events
On June 17, 2025, the Board of Directors of
Aspire Biopharma Holdings, Inc. (the “Company”), changed the Company’s principal executive
office to Estero, Florida. The new principal executive office, principal place of business and headquarters is located at 23150
Fashion Drive, Suite 232, Estero, Florida 33928.
Item 9.01. Financial Statements and Exhibits.
| Exhibit No. |
|
Description |
| 104 |
|
Cover Page Interactive Data File (embedded with the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
ASPIRE BIOPHARMA HOLDINGS, INC. |
| |
|
|
| |
By: |
/s/ Ernest Scheidemann |
| |
|
Ernest Scheidemann |
| |
|
Chief Financial Officer |
| |
|
|
| Date: June 18, 2025 |
|
|
